ORAGENICS INC
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF OPERATIONS
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $2,392,658 | $4,114,434 |
| General and administrative | 6,969,845 | 6,444,381 |
| Total operating expenses | 9,362,503 | 10,558,815 |
| Loss from operations | (9,362,503) | (10,558,815) |
| Other income (expense): | ||
| Interest income | 182,229 | 45,897 |
| Interest expense | (785,930) | (29,828) |
| Foreign currency exchange, net | (13,193) | (25,172) |
| Total other income (expense), net | (616,894) | (9,103) |
| Loss before income taxes | (9,979,397) | (10,567,918) |
| Income tax benefit | 136,910 | - |
| Net loss | $(9,842,487) | $(10,567,918) |
| Basic and diluted net loss per share | $(4.56) | $(47.88) |
| Weight average shares outstanding, basic and diluted | 2,157,076 | 220,731 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.